Home Arthritis FDA Seek to Approve Febuxostat for Gout Despite Potential CV Risks

FDA Seek to Approve Febuxostat for Gout Despite Potential CV Risks

266
0
Gout

Medscape reports that the FDA’s Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee voted by a large margin (19 yes, 2 no 1 abstention) to still recommend febuxostat (Uloric, Takeda) for some patients with gout-related hyperuricemia after a discussion of post marketing study showing possible cardiovascular risk.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.